# Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

> **NCT06995872** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** rhIL-15
- **DRUG:** Dinituximab
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan Hydrochloride

## Key facts

- **NCT ID:** NCT06995872
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-21
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06995872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06995872, "Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06995872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*